Treatment of osteoporosis with recombinant parathyroid hormone, utilisation of total body DXA to observe treatment effects on total body composition and factors determining response to therapy

ConclusionsHypercalciuria which is a frequent feature in osteoporotic population may predict non-responders at 6  months of rPTH, and it may help to optimise individual patient’s treatment. Unlike endogenous PTH in pathological conditions, rPTH is anabolic to bone and has no detrimental effects on the body fat and muscle composition.
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research